Vor Biopharma Inc expected to post a loss of 43 cents a share - Earnings Preview

Vor Biopharma

07/08/2023 12:56

* Vor Biopharma Inc  VOR.OQ   VOR.O  is expected to show no
change
in quarterly revenue when it reports  results on August 9
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Vor Biopharma Inc
is for
a loss of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vor
Biopharma Inc
is $17.5​, above​ its last closing price of $2.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.39       -0.38      -0.43     Missed  -12.2
 Dec. 31 2023  -0.47       -0.60      -0.52     Beat    13.7
 Sep. 30 2022  -0.60       -0.61      -0.63     Missed  -3.7​
 Jun. 30 2022  -0.66       -0.66      -0.58     Beat    11.9
 ​​Mar.        -0.52       -0.51      -0.61     Missed  -18.9
 31 2022                                                
 Dec. 31 2021  -0.52       -0.57      -0.48     Beat    15.2​
 Sep. 30 2021  -0.61       -0.62      -0.50     Beat    19.7
 Jun. 30 2021  -0.47       -0.50      -0.50     Met     0.5
 This summary was machine generated August 7 at 11:56 GMT.  All
figures in US dollars  unless otherwise stated